Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M94,428Revenue $M35,367Net Margin (%)41.4Altman Z-Score2.0
Enterprise Value $M114,556EPS $6.0Operating Margin %46.9Piotroski F-Score7
P/E(ttm)7.1Beneish M-Score-1.9Pre-tax Margin (%)47.8Higher ROA y-yY
Price/Book9.910-y EBITDA Growth Rate %0.5Quick Ratio1.0Cash flow > EarningsN
Price/Sales2.95-y EBITDA Growth Rate %-5.1Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow29.7y-y EBITDA Growth Rate %65.5ROA % (ttm)20.9Higher Current Ratio y-yY
Dividend Yield %5.8PEG--ROE % (ttm)163Less Shares Outstanding y-yY
Payout Ratio %40.0Shares Outstanding M2,171ROIC % (ttm)52.5Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKKen Fisher 2015-06-30 Add0.06%$41.65 - $48.23
($45.06)
$ 43.44-4%Add 7.22%11,533,371
GSKCharles Brandes 2015-03-31 Add0.38%$41.68 - $48.81
($45.86)
$ 43.44-5%Add 18.20%3,879,073
GSKNWQ Managers 2015-03-31 Add0.14%$41.68 - $48.81
($45.86)
$ 43.44-5%Add 123.03%456,380
GSKKahn Brothers 2015-03-31 Add0.06%$41.68 - $48.81
($45.86)
$ 43.44-5%Add 14.12%58,200
GSKDodge & Cox 2015-03-31 Reduce-0.02%$41.68 - $48.81
($45.86)
$ 43.44-5%Reduce 2.18%23,436,551
GSKHOTCHKIS & WILEY 2015-03-31 Add0.01%$41.68 - $48.81
($45.86)
$ 43.44-5%Add 0.73%12,302,975
GSKJoel Greenblatt 2015-03-31 Add$41.68 - $48.81
($45.86)
$ 43.44-5%Add 0.41%83,578
GSKTweedy Browne 2015-03-31 Reduce$41.68 - $48.81
($45.86)
$ 43.44-5%Reduce 2.19%131,346
GSKKen Fisher 2015-03-31 Reduce$41.68 - $48.81
($45.86)
$ 43.44-5%Reduce 0.07%10,757,080
GSKDodge & Cox 2014-12-31 Reduce-0.64%$41.3 - $47.14
($44.76)
$ 43.44-3%Reduce 37.91%23,959,301
GSKHOTCHKIS & WILEY 2014-12-31 Add0.21%$41.3 - $47.14
($44.76)
$ 43.44-3%Add 13.04%12,213,885
GSKDavid Dreman 2014-12-31 Sold Out -0.01%$41.3 - $47.14
($44.77)
$ 43.44-3%Sold Out0
GSKDodge & Cox 2014-09-30 Reduce-1.11%$46.29 - $54.52
($49.01)
$ 43.44-11%Reduce 35.93%38,589,161
GSKHOTCHKIS & WILEY 2014-09-30 Add0.98%$46.29 - $54.52
($49.01)
$ 43.44-11%Add 118.31%10,804,564
GSKCharles Brandes 2014-09-30 Add0.56%$46.29 - $54.52
($49.01)
$ 43.44-11%Add 36.63%3,415,717
GSKKahn Brothers 2014-09-30 Buy 0.38%$46.29 - $54.52
($49.01)
$ 43.44-11%New holding51,000
GSKNWQ Managers 2014-09-30 Add0.03%$46.29 - $54.52
($49.01)
$ 43.44-11%Add 39.82%208,125
GSKDavid Dreman 2014-09-30 Buy 0.01%$46.29 - $54.52
($49.01)
$ 43.44-11%New holding1,328
GSKHOTCHKIS & WILEY 2014-06-30 Add0.93%$51.55 - $56.39
($54.16)
$ 43.44-20%Add 13358.60%4,949,118
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 43.44-20%Add 15.52%2,500,048
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$2297.45view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.14105.49view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29721.17view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12262view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14210.29view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12262view

Quarterly/Annual Reports about GSK:

    News about GSK:

    Articles On GuruFocus.com
    It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
    Tweedy Browne Global Value Adds to Eight Stakes in Portfolio Jul 14 2015 
    JW1 Jun 29 2015 
    JW1 Jun 28 2015 
    JW1 Jun 28 2015 
    JW1 Jun 28 2015 
    Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK Jun 15 2015 
    Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK Jun 14 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Hotchkis & Wiley Large Cap Value Fund Q1 2015 Commentary May 22 2015 

    More From Other Websites
    Ebola game changer? Jul 31 2015
    There's more to Merck's Ebola vaccine than money Jul 31 2015
    A game changer for Ebola cure Jul 31 2015
    After Merck success, work goes on with other Ebola vaccines Jul 31 2015
    After Merck success, work goes on with other Ebola vaccines Jul 31 2015
    Is GlaxoSmithKline plc More Likely To Double In Value Than Hikma Pharmaceuticals Plc? Jul 31 2015
    Brilinta? Brintellix? FDA warns of drug name mix-ups Jul 30 2015
    Brilinta? Brintellix? FDA warns of drug name mix-ups Jul 30 2015
    GlaxoSmithKline (GSK) Earnings Report: Q2 2015 Conference Call Transcript Jul 30 2015
    Should You Splash The Cash On GlaxoSmithKline plc, Bodycote PLC And RPS Group plc? Jul 30 2015
    Glaxo Up on Q2 Earnings Beat, Revenues Rise, View Same - Analyst Blog Jul 30 2015
    Advair revenue down again, but GSK looks to next-gen (and Zebulon) for replacement revenue Jul 29 2015
    GlaxoSmithKline sees staged roll-out of malaria vaccine Jul 29 2015
    Exclusive - GSK faces new corruption allegations, this time in Romania Jul 29 2015
    Exclusive - GSK faces new corruption allegations, this time in Romania Jul 29 2015
    Exclusive - GSK faces new corruption allegations, this time in Romania Jul 29 2015
    Exclusive: GSK faces new corruption allegations, this time in Romania Jul 29 2015
    GSK Boosted by New Vaccines Jul 29 2015
    4 Stocks, 4 trades: Gilead, Altria & more Jul 29 2015
    GSK jumps 3% on strong EPS; Advair sales slump Jul 29 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK